Effect of Renin-angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It enrolled 1400 participants.
Also called NCT01500590
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,400 participants
- Sponsor
- Hospital Authority, Hong Kong
- Registry
-
NCT01500590
-
- Start date
- (registry gives no type)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT01500590. Randomized; no masking; primary purpose treatment. Start 2011-11 (registry gives no type); primary completion 2018-08 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Renin-angiotensin System Blockers on Glomerular Filtration Rate in Patients With Hypertension, Type 2 Diabetes With Normoalbuminuria
- Acronym
- eGFR
- Condition
- Diabetes
- Condition
- Hypertensive Disease
- Intervention (Drug)
- Renin-angiotensin system blockers
- Intervention (Drug)
- non-renin angiotensin system blockers
- Lead sponsor
- Hospital Authority, Hong Kong
Record details
- Record id
cardio:ct-nct01500590- Content hash
5b2d815a41286f5cd47b6fd8e1d4792454613333073992e56b0b764ebc6466c5